Stem cell transplantation and intensified cytotoxic treatment for myelodysplasia

Current Opinion in Hematology

Volumn 5, Issue 6, 1998, Pages 465-471

  Boogaerts, Marc A ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; BUSULFAN; CYCLOSPORIN A; CYTARABINE; CYTOTOXIC AGENT; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IDARUBICIN; MITOXANTRONE; T LYMPHOCYTE ANTIBODY;

ALLOTRANSPLANTATION; APLASTIC ANEMIA; AUTOTRANSPLANTATION; CLINICAL TRIAL; CYTOPENIA; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; MORBIDITY; MORTALITY; MYELODYSPLASTIC SYNDROME; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REMISSION; REVIEW; SIBLING; SURVIVAL; TREATMENT PLANNING;

EID: 0031743375     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199811000-00019     Document Type: Review

References (38)

1. Boogaerts MA, Verhoef G, Demuynck H.: Treatment and prognostic factors in myelodysplastic syndromes. Baillieres Clin Haematol 1996, 9:161-183.
2. Greenberg P, Cox C, Le Beau M, et al.: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
3. Tricot G, Boogaerts M.: The role of aggressive chemotherapy in the treatment of the myelodysplastic syndromes. Br J Haematol 1986, 63:477-483.
4. De Witte T, Suciu S, Peetermans P, Fenaux P: Intensive chemotherapy for poor prognosis myelodysplasia and secondary acute myeloid leukemia following MDS of more than 6 months duration. A pilot study by the leukemia cooperative group of the EORTC. Leukemia 1995, 9:1805-1811.
5. Ruutu T, Hänninen A, Järvenie G, et al.: Intensive chemotherapy of poor prognosis myelodysplastic syndromes and acute myeloid leukemia following MDS with idarubicin and fludarabine. Leuk Res 1997, 21:133-138.
6. Bernstein S, Brunetto V, Davey F, et al.: Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a cancer and leukemia group B Study. J Clin Oncol 1996, 14:2486-2494.
7. Gardin C, Chaibi P, De Revel T, et al.: Intensive chemotherapy with idarubicin, cytosine arabinoside and G-CSF in patients with secondary leukemia. Leukemia 1997, 11:16-21.
8. Wattel E, De Botton S, Lai JL, Fenaux P: Long-term follow-up of de novo myelodysplastic syndromes treated with intensive chemotherapy: incidence of long-term survivors and outcome of partial responders. Br J Haematol 1997, 98:983-991.
9. Gandhi V, Estey E, Keating M, Plunkett W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 1993, 11:497-501.
10. Estey E, Thall P, Andreef M et al.: Use of granulocyte colony stimulating factor before, during and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia and myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony stimulating factor. J Clin Oncol 1994, 12:671-678.
11. Parker JE, Pagliuca A, Mijovic A, et al.: Fludarabine, cytarabine, G-CSF and idarubicin (Flag-Ida) for the treatment of poor risk myelodysplastic syndromes and acute myeloid leukaemia. Br J Hematol 1997, 99:939-944.
12. Sierra J, Carreras E, Rozman C, et al.: Bone marrow transplantation for myelodysplasia: the IBMTR data. Leuk Res 1997, 21 (suppl 1):S51.
13. De Witte T, Zwaan F, Hermans J. Allogeneic bone marrow transplantation for secondary leukemia and myelodysplastic syndrome: a survey by the Leukemia Working Party of the EBMT. Br J Haematol 1990, 74:151-155.
14. Anderson J, Gooley T, Schoch G, et al.: Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. Blood 1997, 89:2578-2585.
15. Anderson JE, Thomas ED.: The Seattle experience with bone marrow transplantation for myelodysplasia. Leuk Res 1997, 21s:51.
16. Demuynck H, Verhoef G, Emonds MP, Van der Schueren E, Vandenberghe H, Boogaerts M.: Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical siblings and alternative donors. Bone Marrow Transplant 1996, 17:745-751.
17. Ballen KK, Gilliland DG, Guinan EC, et al.: Bone marrow transplantation for therapy related myelodysplasia: comparison with primary myelodysplasia. Bone Marrow Transplantation 1997, 20:737-743.
18. Anderson JE, Anasetti C, Appelbaum FR. Unrelated donor bone marrow transplantation for myelodysplasia and MDS related acute myeloid leukemia. Br J Haematol 1996, 93:59-67.
19. Anderson J, Appelbaum F, Schoch G, et al.: Allogeneic marrow transplantation for refractory anemia. A comparison of two preparative regimens and analysis of prognostic factors. Blood 1996, 87:51-58.
20. Slavin S, Nagler A, Naparstek E, et al.: Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998, 91:756-763.
21. Giralt S, Estey E, Albtar M, et al.: Engraftment of allogeneic hematopoietic progenitor cells with purine analog containing chemotherapy: harnessing graft versus leukemia without myeloablative therapy. Blood 1997, 89:4531-4538.
22. Porter DL, Roth MS, Lee SJ, et al.: Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic transplantation. Bone Marrow Transplant 1996, 18:975-980.
23. Collins RH, Shpilberg O, Drobyski WR, et al.: Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997, 15:433-444.
24. Okamura H, Takamatsu H, Yoshida T, et al.: Donor leukocyte transfusions for relapse in myelodysplastic syndrome after allogeneic marrow transplantation. Br J Haematol 1996, 93:386-388.
25. Demuynck H, Delforg M, Verhoef G, Zachee P, Vandenberghe H, Boogaerts M.: Feasibility of peripheral blood progenitor cell harvest and transplantation in patients with poor-risk myelodysplastic syndromes. Br J Haematol 1996,92:351-359.
26. Carella AM, Dejana A, Lerma E.: In vivo mobilisation of karyotypically normal peripheral blood progenitor cells in high-risk MDS, secondary or therapy-related acute myelogenous leukemia. Br J Haematol 1996, 95:127-130.
27. Wattel E, Solary E, Caillot D, et al.: Autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Leuk Res 1997, 21(suppl 1):S52.
28. De Witte T, Van Biezen A, Hermans J, et al.: Autologous bone marrow transplantation for patients with myelodysplastic syndromes or acute myeloid leukemia following MDS. Blood 1997, 90:3853-3857.
29. Delforge M, Demuynck H, Vandenberghe P, Boogaerts M.: Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes. Blood 1995, 86:3660-3667.
30. Passmore SJ, Hahn IM: Paediatric myelodysplasia. Br Med Bulletin 1996, 52:778-786.
31. Barnard DR, Kalousek DK, Wiersma SR, et al.: Morphologic, immunologic and cytogenetic classification of acute myeloid leukemia and myelodys-plastic syndrome in childhood. A report from the Children's Cancer Group Leukemia 1996, 10:5-11.
32. Niemeyer CM, Arico M, Basso A, et al.: Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. Blood 1997, 89:3534-3543.
33. Locatelli F, Niemeyer C, Angelucci E, et al.: Allogeneic bone marrow transplantation for chronic myelomonocytic leukemia in childhood. J Clin Oncol 1997, 15:566-573.
34. Creutzig U, Bender-Götze C, Ritter J, et al.: The role of intensive AML-specific therapy in treatment of children with RAEB and RAEB-t. Leukemia 1998, 12:652-659.
35. Locatelli F, Zecca M, Niemeyer C, et al.: Role of allogeneic bone marrow transplantation for the treatment of myelodysplastic syndromes in childhood. Bone Marrow Transplant 1996, 18 (Suppl 2):63-68.
36. Davies SM, Wagner JE, Defor T, et al.: Unrelated donor bone marrow transplantation for children and adolescents with aplastic anemia or myelodysplasia. Br J Hematol 1997, 96:749-756.
37. Hasle H, Kemdrup G, Yssing M, et al.: Intensive chemotherapy in childhood myelodysplastic syndrome. A comparison with results in acute myeloid leukemia. Leukemia 1996, 10:1269-1273.
38. Nagatoshi Y, Okamura J, Ikuno Y, et al.: Therapeutic trial of intensified conditioning regimen with high dose cytosine arabinoside, cyclophosphamide and either total body irradiation or busulfan followed by allogeneic transplantation for myelodysplastic syndromes in children. Intl J Hematol 1997, 65:269-275.